Natrecor Sales & Marketing Subject Of Federal Prosecutor's Subpoena
This article was originally published in The Pink Sheet Daily
Executive Summary
U.S. Attorney's Office in Boston is seeking "documents related to the sales and marketing" of the congestive heart failure therapy, J&J division Scios says. Subpoena announcement comes on the heels of a journal article asserting that Scios engaged in a marketing campaign for outpatient use of the drug, which the company denies.
You may also be interested in...
CMS Proposes To Cover J&J's Natrecor For Labeled Indication Only
CMS' proposed national coverage determination would not provide Medicare coverage of nesiritide for chronic heart failure.
CMS Proposes To Cover J&J's Natrecor For Labeled Indication Only
CMS' proposed national coverage determination would not provide Medicare coverage of nesiritide for chronic heart failure.
Procrit Could Return To Growth Later This Year, J&J Says
Anemia therapy should reverse a quarterly sales decline brought on by competition from Amgen, Johnson & Johnson maintains. Worldwide sales were up for the second quarter.